Molidustat vs SSS17

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline

Molidustat

Marketed by Bayer

Phase 3 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT03543657 · Phase 3 · completed

The trial randomized 229 participants to molidustat or darbepoetin alfa with matching placebos and quadruple blinding. Its primary endpoints were hemoglobin measures, which are laboratory surrogate outcomes. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

The mean Hb level during the evaluation period (From week 33 to 36); The change in mean Hb level during the evaluation period from baseline (Baseline and week 33 to 36): Mean Hb during evaluation period (weeks 33-36): molidustat 10.63 g/dL (95% CI 10.42-10.84) vs darbepoetin alfa 10.77 g/dL (95% CI 10.59-10.95); LS mean difference -0.13 g/dL (95% CI -0.46 to 0.19); noninferiority (margin 1.0 g/dL) established (met)

Result source: NCT03543657

SSS17

Developed by Shenyang Sunshine Pharmaceutical

Phase 2 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT07014631 · Phase 2 · completed

The study randomized 86 participants to SSS17 or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in hemoglobin, a laboratory surrogate measure, and the comparison has not been reported, so no conclusion can yet be drawn about whether the endpoint was met.

No aligned efficacy figure on record for this race.

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMolidustatSSS17
Kidney composite outcome—Not posted · NCT03350347—Not reported
UACR, % change—Not posted · NCT03350347—Not reported
eGFR slope—Not posted · NCT03350347—Not reported
Haemoglobin, change—Not posted · NCT03350347—Not reported

Kidney composite outcome

Molidustat
—Not posted · NCT03350347
SSS17
—Not reported

UACR, % change

Molidustat
—Not posted · NCT03350347
SSS17
—Not reported

eGFR slope

Molidustat
—Not posted · NCT03350347
SSS17
—Not reported

Haemoglobin, change

Molidustat
—Not posted · NCT03350347
SSS17
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SSS17: no structured comparison results are available for Chronic Kidney Disease.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Molidustat

Hgb Target Range 54.9%
responder rate · % of participants
No placebo or comparator arm
NCT03418168 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Molidustat's landscape · SSS17's landscape